Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$40.39 +1.9%	$32.24	$16.50 ▼ $43.58	$3.52B	N/A	47,045 shs	6,808 shs
IMVT Immunovant	$17.91 -2.0%	$15.78	$12.72 ▼ $34.47	$3.06B	0.63	1.22 million shs	944,280 shs
MLTX MoonLake Immunotherapeutics	$53.09 -2.0%	$44.23	$31.42 ▼ $58.26	$3.40B	1.27	385,298 shs	363,198 shs
SNDX Syndax Pharmaceuticals	$9.46 -2.2%	$9.91	$8.58 ▼ $25.07	$814.03M	0.7	1.86 million shs	1.90 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+2.59%	-2.75%	+25.22%	+111.65%	+3,961,999,900.00%
IMVT Immunovant	+2.64%	+4.46%	+19.40%	+20.66%	-39.03%
MLTX MoonLake Immunotherapeutics	+3.16%	+10.84%	+26.00%	+41.35%	+16.57%
SNDX Syndax Pharmaceuticals	+4.54%	-1.53%	+0.31%	-15.95%	-59.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	1.5207 of 5 stars	3.4	0.0	0.0	0.0	2.8	1.7	0.0
MLTX MoonLake Immunotherapeutics	2.0663 of 5 stars	3.5	1.0	0.0	0.0	2.7	2.5	0.0
SNDX Syndax Pharmaceuticals	3.0868 of 5 stars	3.5	0.0	0.0	4.4	2.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
IMVT Immunovant	2.82	Moderate Buy	$36.30	101.96% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$74.50	38.99% Upside
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.10	257.89% Upside

Current Analyst Ratings Breakdown

Latest SNDX, MLTX, IMVT, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
6/3/2025	MLTX MoonLake Immunotherapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$78.00 ➝ $80.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/30/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	26.24	N/A	N/A	$0.48 per share	84.31
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	34.62	N/A	N/A	$3.38 per share	2.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)

Latest SNDX, MLTX, IMVT, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$0.99	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
IMVT Immunovant	N/A	11.16	11.16
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
IMVT Immunovant	47.08%
MLTX MoonLake Immunotherapeutics	93.85%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
IMVT Immunovant	1.80%
MLTX MoonLake Immunotherapeutics	12.02%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.32 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable

SNDX, MLTX, IMVT, and AAPG Headlines

Recent News About These Companies

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Makes New $2.46 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

July 18 at 10:01 AM | marketbeat.com

UBS Group Cuts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $35.00

July 18 at 4:05 AM | americanbankingnews.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% Following Analyst Downgrade

July 17 at 2:27 AM | americanbankingnews.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts

July 16 at 2:04 AM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst Downgrade

July 15 at 2:45 PM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group

July 15 at 11:19 AM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

July 12, 2025 | msn.com

The Goldman Sachs Group Initiates Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)

July 10, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7% - Time to Buy?

July 9, 2025 | marketbeat.com

Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

July 9, 2025 | msn.com $https://www.msn.com/en-us/money/general/syndax-s-revuforj-granted-fda-priority-review-for-relapsed-refractory-mutant-npm1-aml/ar-AA1IeAsC$

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

July 8, 2025 | seekingalpha.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Syndax Pharmaceuticals Inc News (SNDX) - Investing.com

June 26, 2025 | investing.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Morningstar

June 25, 2025 | morningstar.comM

Syndax Gets Priority Review for Leukemia Drug Application

June 24, 2025 | marketwatch.com

Syndax stock rises after FDA grants Priority Review for cancer drug expansion

June 24, 2025 | investing.com

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

June 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX, MLTX, IMVT, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$40.39 +0.77 (+1.94%)

As of 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Immunovant NASDAQ:IMVT

$17.91 -0.37 (-2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$18.03 +0.12 (+0.66%)

As of 04:34 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

MoonLake Immunotherapeutics NASDAQ:MLTX

$53.09 -1.09 (-2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$53.22 +0.13 (+0.24%)

As of 04:04 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.46 -0.21 (-2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$9.70 +0.24 (+2.54%)

As of 04:21 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time